Literature DB >> 28604747

GATA3 interacts with and stabilizes HIF-1α to enhance cancer cell invasiveness.

M-C Lin, J-J Lin, C-L Hsu, H-F Juan, P-J Lou, M-C Huang.   

Abstract

This corrects the article DOI: 10.1038/onc.2017.8.

Entities:  

Year:  2017        PMID： 28604747      PMCID： PMC5537603          DOI： 10.1038/onc.2017.196

Source DB:  PubMed          Journal:  Oncogene        ISSN： 0950-9232            Impact factor:   9.867


Correction to: Oncogene (2017) 36, 4243–4252; doi: 10.1038/onc.2017.8; published online 6 March 2017 The authors noted an error in the bottom panel of Figure 2c. A revised version is shown below and the text of the manuscript remains unchanged.

Figure 2

Figure 2 The authors would like to apologize for any inconvenience caused and confirm that the conclusions drawn from this research are not affected by this error.
  4 in total

1.  FMNL1 Exhibits Pro-Metastatic Activity via CXCR2 in Clear Cell Renal Cell Carcinoma.

Authors:  Mei-Fang Zhang; Qiu-Li Li; Yu-Feng Yang; Yun Cao; Chris Zhiyi Zhang
Journal:  Front Oncol       Date:  2020-11-26       Impact factor: 6.244

2.  Olfm4 Is Highly Expressed in HCC Patients and as a Biomarker and Therapeutic Target for HCC.

Authors:  Yulong Wei; Qingzhu Song; Fenglan Zhang; Tian Yuan
Journal:  Can J Gastroenterol Hepatol       Date:  2021-12-06

3.  LncRNA LINRIS stabilizes IGF2BP2 and promotes the aerobic glycolysis in colorectal cancer.

Authors:  Yun Wang; Jia-Huan Lu; Qi-Nian Wu; Ying Jin; De-Shen Wang; Yan-Xing Chen; Jia Liu; Xiao-Jing Luo; Qi Meng; Heng-Ying Pu; Ying-Nan Wang; Pei-Shan Hu; Ze-Xian Liu; Zhao-Lei Zeng; Qi Zhao; Rong Deng; Xiao-Feng Zhu; Huai-Qiang Ju; Rui-Hua Xu
Journal:  Mol Cancer       Date:  2019-12-02       Impact factor: 27.401

Review 4.  Autonomous glucose metabolic reprogramming of tumour cells under hypoxia: opportunities for targeted therapy.

Authors:  Mingyao Huang; Liang Yang; Xueqiang Peng; Shibo Wei; Qing Fan; Shuo Yang; Xinyu Li; Bowen Li; Hongyuan Jin; Bo Wu; Jingang Liu; Hangyu Li
Journal:  J Exp Clin Cancer Res       Date:  2020-09-14
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.